IntegraGen Receives $2.4M from French Investment Firm | GenomeWeb

NEW YORK (GenomeWeb News) – Molecular diagnostics firm IntegraGen said on Thursday it has received €2 million ($2.4 million) in financing from funds managed by French private investment firm A Plus Finance.

The funds will go toward the continued development of genetic tests for colorectal cancer and liver cancer, Integragen, also based in France, said, and to accelerate R&D and commercialization efforts directed at molecular diagnostics for autism.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.